US8436032B2 - Bendamustine cyclopolysaccharide compositions - Google Patents

Bendamustine cyclopolysaccharide compositions Download PDF

Info

Publication number
US8436032B2
US8436032B2 US12/711,979 US71197910A US8436032B2 US 8436032 B2 US8436032 B2 US 8436032B2 US 71197910 A US71197910 A US 71197910A US 8436032 B2 US8436032 B2 US 8436032B2
Authority
US
United States
Prior art keywords
bendamustine
composition
sbecd
solution
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US12/711,979
Other languages
English (en)
Other versions
US20100216858A1 (en
Inventor
Tomasz Popek
Kishore Patel
Valery Alakhov
Grzegorz Pietrzynski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Softkemo Pharma Corp
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42631521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US8436032(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to RU2016124871A priority Critical patent/RU2734236C2/ru
Priority to AU2010217297A priority patent/AU2010217297A1/en
Priority to ES10745872.1T priority patent/ES2525257T3/es
Priority to EP10745872.1A priority patent/EP2400987B1/de
Priority to JP2011550669A priority patent/JP5654498B2/ja
Priority to CN2012104076231A priority patent/CN102935080A/zh
Priority to CA2753641A priority patent/CA2753641C/en
Priority to US12/711,979 priority patent/US8436032B2/en
Priority to PCT/IB2010/000502 priority patent/WO2010097700A1/en
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Priority to CN2010800183017A priority patent/CN102421451B/zh
Priority to KR1020117022330A priority patent/KR101798951B1/ko
Priority to RU2011138844/15A priority patent/RU2591804C2/ru
Publication of US20100216858A1 publication Critical patent/US20100216858A1/en
Assigned to SUPRATEK PHARMA INC. reassignment SUPRATEK PHARMA INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALAKHOV, VALERY, PATEL, KISHORE, PIETRZYNSKI, GRZEGROZ, POPEK, THOMASZ
Priority to US13/793,442 priority patent/US8703964B2/en
Publication of US8436032B2 publication Critical patent/US8436032B2/en
Application granted granted Critical
Assigned to SOFTKEMO PHARMA CORP. reassignment SOFTKEMO PHARMA CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SUPRATEK PHARMA INC.
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • the present invention is directed to compositions of (a) bendamustine, (b) a charged cyclopolysaccharide, and (c) a stabilizing agent.
  • Bendamustine 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid, is used in the treatment of leukemia and certain lymphomas.
  • this compound has limited chemical stability in plasma, thereby requiring high or repeated doses in order to achieve a therapeutic effect.
  • formulations of this drug which will exhibit increased stability.
  • the present invention is directed to a composition
  • a composition comprising: (a) bendamustine, (b) a charged cyclopolysaccharide, and (c) a stabilizing agent; preferably a stabilizing agent having a charge opposite to that of the cyclopolysaccharide.
  • a stabilizing agent preferably a stabilizing agent having a charge opposite to that of the cyclopolysaccharide.
  • Such composition provides unexpectedly desirable stability in reactive environments such as plasma, coupled with unexpectedly desirable anticancer activity.
  • Such composition is suitable for injection or infusion into patients in need of treatment with bendamustine.
  • the present invention is directed to a composition
  • a composition comprising: (a) bendamustine, (b) a charged cyclopolysaccharide, and (c) a stabilizing agent having a charge opposite to that of the cyclopolysaccharide.
  • the proportion of active ingredient to cyclopolysaccharide, by weight is between about 1:12,500 and about 1:25; is more preferably between about 1:5,000 and about 1:50; is even more preferably between about 1:2,500 and about 1:75 and most preferably between about 1:1,500 and 1:100.
  • the stabilizing agent is typically present in a weight ratio to the cyclopolysaccharide of between about 5:1 and about 1:1000; preferably of between about 2:1 and about 1:200.
  • cyclopolysaccharides which may employed in the practice of this invention include cyclodextrins, cyclomannins, cycloaltrins, cyclofructins and the like. In general, cyclopolysaccharides comprising between 6 and 8 sugar units are preferred.
  • cyclopolysaccharides which may be employed are cyclodextrins.
  • Cyclodextrins are cyclic oligo-1-4-alpha-D-glucopyranoses comprising at least 6 sugar units. The most widely known are cyclodextrins containing six, seven or eight sugar units. Cyclodextrins containing six sugar units are known as alpha-cyclodextrins, those containing seven sugar units are known as beta-cyclodextrins and those consisting of eight sugar units are known as gamma-cyclodextrins. Particularly preferred cyclopolysaccharides are beta-cyclodextrins.
  • the cyclopolysaccharides employed are modified with one or more chargeable groups.
  • chargeable groups may be anionic, in which case the stabilizing agent is cationic; or such charged groups may be cationic, in which case the stabilizing agent is anionic.
  • Preferred anionic groups include carboxyl, sulfonyl and sulphate groups; while preferred cationic groups include quarternary ammonium groups.
  • charged cyclopolysaccharide refers to a cyclopolysaccharide having one or more of its hydroxyl groups substituted or replaced with a chargeable moiety.
  • Such moiety may itself be a chargeable group (e.g., such as a sulfonyl group) or it may comprise an organic moiety (e.g., a C 1 -C 6 alkyl or C 1 -C 6 alkyl ether moiety) substituted with one or more chargeable moieties.
  • Preferred substituted cyclopolysaccharides include, but are not limited to, sulfobutyl ether beta-cyclodextrin, beta-cyclodextrin substituted with 2-hydroxy-N,N,N-trimethylpropanammonium, carboxymethylated-beta-cyclodextrin, O-phosphated-beta-cyclodextrin, succinyl-(2-hydroxy)propyl-beta-cyclodextrin, sulfopropylated-beta-cyclodextrin, heptakis(6-amino-6-deoxy)beta-cyclodextrin, O-sulfated-beta-cyclodextrin, and 6-monodeoxy-6-mono(3-hydroxy)propylamino-b-cyclodextrin; with sulfobutyl ether beta-cyclodextrin being particularly preferred.
  • the stabilizing agent is selected from cationic agents, or from polycationic compounds.
  • Cationic agents which may be employed include primary amines, secondary amines, tertiary amines or quaternary ammonium compounds, such as N-alkyl-N,N-dimethylamines, N-alkyl-N,N-diethylamines, N-alkyl-N—N-diethanoloamines, N-alkylmorpholine, N-alkylpiperidine, N-alkylpyrrolidine, N-alkyl-N,N,N-trimethylammonium, N,N-dialkyl-N,N-dimethylammonium, N-alkyl-N-benzyl-NN-diimethylammonium, N-alkyl-pyridinium, N-alkyl-picolinium, alkylamidomethylpyridinium, carbalkoxypyri
  • Particularly preferred cationic adjuvants include sterically hindered tertiary amines, such as N-alkyl-N—N-diisopropylamine, N-alkylmorpholine, N-alkylpiperidine, and N-alkylpyrrolidine; and quaternary ammonium compounds such as cetylpyridinium chloride, benzyldimethyldodecylammonium chloride, dodecylpyridinium chloride, hexadecyltrimethylammonium chloride, benzyldimethyltetradecylammonium chloride, octadecyldimethylbenzylammonium chloride, and domiphen bromide.
  • sterically hindered tertiary amines such as N-alkyl-N—N-diisopropylamine, N-alkylmorpholine, N-alkylpiperidine, and N-alkylpyr
  • Polycationic compounds such as oligo- or polyamines, or pegylated oligo- or polyamines may also be employed as the stabilizing agent.
  • Preferred polycationic compounds include oligoamines such as spermine, spermidin, putrescine, and cadaverine; polyamines: such as polyethyleneimine, polyspermine, polyputrescine, and polycadaverine; and pegylated oligoamines and polyamines of the group listed above. Particularly preferred is PI2080, polyethyleneimine 2000 conjugated with PEG 8000.
  • One preferred class of cationic stabilizing agents are polypeptides comprising from about 5 to about 50, more preferably between about 6 and about 20, amino acids; wherein at least about 50% of such amino acids contain a positive charge. Most preferably, such charged amino acid is arginine.
  • Particularly preferred members of this class of peptides include arginine rich peptides comprising at least one block sequence of 4 arginines.
  • Another particularly preferred member of this class of peptides is protamine which has been digested with thermolysin (hereinafter referred to as Low Molecular Weight Protamine or “LMWP”).
  • LMWP Low Molecular Weight Protamine
  • Hydrophobically modified oligo- or polyamines may also be employed.
  • Preferred stabilizing agent of this type include acetyl spermine, acetyl polyspermine, acetyl polyethyleneimine, butyryl spermine, butyryl polyspermine, butyryl polyethyleneimine, lauroyl spermine, lauroyl polyspermine, lauroyl polyethyleneimine, stearoyl spermine, stearoyl polyspermine, and stearoyl polyethyleneimine,
  • cationic polysaccharides and synthetic polycationic polymers may also be employed.
  • Illustrative of such cationic polysaccharides are chitosan, deacetylated chitosan, quaternized cellulose, quaternized amylo se, quaternized amylopectine, quaternized partially hydrolyzed cellulose, quaternized partially hydrolyzed amylose and quaternized partially hydrolyzed amylopectine.
  • Polyquaternium 2 poly[bis(2-chloroethyl]ether-alt-1,3-bis[3-dimethylamino)propyl]-urea quaternized
  • Polyquaternium 11 poly(1-vinylpyrrolidone-co-dimethylammonioethyl methacrylate) quaternized
  • Polyquaternium 16 and 44 copolymer of vinylpyrrolidone and quaternized vinylimidazole
  • Polyquaternium 46 copolymer of vinylcaprolactam, vinylpyrrolidone and quaternized vinylimidazole).
  • the stabilizing agent is selected from anionic agents, or from polyanionic polymers.
  • such anionic agent is selected from compounds comprising a carboxy-, sulfate-, sulfono-, phosphate-, or phosphono-group.
  • anionic agents such as sodium 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, sodium N-lauroylsarcosinate, sodium dodecyl sulfate, sodium dodecylbenzylsulfonate and the like.
  • Cationic polysaccharides may also be employed as the stabilizing agent.
  • Illustrative of such compounds are chondroitin sulfate, dermatan sulphate, kappa-carrageenan, iota-carrageenan, lambda-carrageenan, mu-carrageenan, xi-carrageenan, psi-carrageenan, tau-carrageenan, furcellaran, heparan sulphate, keratin, fucoidan, hyaluronic acid, alginic acid, poly(sulfonylbutylo)cellulose, poly(sulfonylpropylo)cellulose, poly(sulfonylpropylo)dextran, poly(sulfonylbutylo)dextran, poly(sulfonylbutylo)amylase and poly(sulfonylpropylo)amylase.
  • the stabilizing agent may also be a polyanionic polymer selected from polyacrylates, polymethacrylates, and their copolymers.
  • compositions of this invention may further contain pharmaceutically acceptable excipients, such as sugars, polyalcohols, soluble polymers, salts and lipids.
  • Sugars and polyalcohols which may be employed include, without limitation, lactose, sucrose, mannitol, and sorbitol.
  • soluble polymers which may be employed are polyoxyethylene, poloxamers, polyvinylpyrrolidone, and dextran.
  • Useful salts include, without limitation, sodium chloride, magnesium chloride, and calcium chloride.
  • Lipids which may be employed include, without limitation, fatty acids, glycerol fatty acid esters, glycolipids, and phospholipids.
  • the stabilizing agent and excipient are preferably introduced to the composition by their addition to a pre-prepared aqueous homogenous and equilibrated solution of bendamustine with the cyclopolysaccharide.
  • Such agents may be added either as pure substances or as aqueous solutions and are preferably mixed employing gentle agitation.
  • the final composition is filtered before use for injection.
  • compositions comprising amines as stabilizing agents are freeze dried prior to the addition of such stabilizing agent, with such agent being introduced into the composition after reconstitution, shortly before use.
  • composition of this invention is prepared by mixing the components and incubation.
  • composition of this invention is prepared by mixing the components and applying ultrasound to the mixture.
  • composition of this invention is prepared by mixing the components, incubation, and freeze-drying the product.
  • composition of this invention is prepared by mixing the components, applying ultrasound to the mixture, and freeze-drying the product.
  • compositions of this invention demonstrate enhanced stability in aqueous solution and when introduced into plasma, both under in vitro and under in vivo conditions.
  • such formulations will exhibit a half-life in plasma which is greater than that of non-formulated bendamustine; which half-life may be extended by more than 50% and preferably more than 100%.
  • compositions of this invention exhibit unexpectedly improved activity against tumors relative to compositions comprising bendamustine and a cyclopolysaccharide; as well as relative to bendamustine alone.
  • bendamustine hydrochloride 6 mg were dissolved in 1 mL of 20% w/w solution of sodium sulfobutyl ether ⁇ -cyclodextrin. The solution was incubated at 20° C. for 15 minutes on ultrasonic bath and mixed with 1 mL of 25% solution of chondroitin sulfate.
  • bendamustine hydrochloride 6 mg are dissolved in 1 ml of 30% w/w solution of sodium sulfobutyl ether ⁇ -cyclodextrin.
  • the solution is preincubated at 10° C. for 15 minutes on ultrasonic bath. After that the solution is mixed with 1 ml of 2% solution of poly(sulfonylbutylo)cellulose sodium salt. The sample is incubated on ultrasonic bath for 30 minutes at 10° C.
  • bendamustine hydrochloride 6 mg were dissolved in 1 mL of 30% w/w solution of sodium sulfobutyl ether ⁇ -cyclodextrin. The solution was preincubated at 10° C. for 15 minutes on ultrasonic bath. After that the solution was mixed with 1 mL of 0.1% solution of hyaluronic acid sodium salt. The sample was incubated on ultrasonic bath for 30 minutes at 10° C.
  • bendamustine hydrochloride 6 mg were dissolved in 1 mL of 20% w/w solution of sodium sulfobutyl ether ⁇ -cyclodextrin. The solution was incubated at 20° C. for 15 minutes on ultrasonic bath and then mixed with 1 mL of 50% solution of dextran 40 (MW 40000) and sonicated for another 15 minutes.
  • bendamustine hydrochloride 6 mg were dissolved in 1 mL of 20% w/w solution of 2-hydroxypropyl- ⁇ -cyclodextrin. The solution was incubated at 20° C. for 15 minutes on ultrasonic bath and then mixed with 1 mL of 50% solution of dextran 40 (MW 40000) and was sonicated for another 15 minutes.
  • Polyethyleneimine (PEI, MW 2000) was purchased from Aldrich.
  • PI2080 a conjugate of PEG and PEI, was prepared following the procedure described by Vinogradov S. V. et al. in Bioconjugate Chem. 1998, 9, 805-812.4 g of PEG was reacted with 1,1′-carbonyldiimidazole in 20 mL anhydrous acetonitrile. The product of the reaction was dialysed twice against water using SpectraPor 3 membrane, MWCO 3500, and freeze-dried.
  • the freeze-dried material was dissolved in 32 mL of methanol, mixed with 2.9 g of PEI and incubated for 24 hours at 25° C.
  • the product was dialysed twice against water using SpectraPor 3 membrane, MWCO 3500, and the product PI2080 was freeze-dried.
  • Control 6 mg/mL bendamustine hydrochloride, 10.2 mg/mL of mannitol in 0.9% NaCl; dose of 20 mg/kg
  • Inventive Composition 5 mg/g bendamustine hydrochloride, 40% w/w sodium sulfobutyl ether ⁇ -cyclodextrin, 0.5% cetylpyridinium chloride, 8.5 mg/g mannitol in water (produced following the procedure of Example 8); dose of 20 mg/kg.
  • mice Female Sprague-Dawley rats (250-350 g). The animals were kept three per cage with an air filter cover under light (12 h light/dark cycle, light on at 06 h00) and controlled temperature 22° C.+/ ⁇ 1° C. All manipulations with the animals were performed under a sterilized laminar hood. The animals had ad libitum access to Purina mouse chow and water. The animals were fasted overnight and anesthetized, before dosing.
  • the inventive bendamustine composition and control were administered intravenously to rats in tail vein. After time intervals of 5, 15, 30, 45 min, 1, 1.5, 2 and 3 hrs post-injection, blood samples were collected. The rats were anesthetized by general inhalation of isoflurane. The blood samples were collected from the jugular vein with heparinized tube and kept on ice. Blood was immediately centrifuged, and plasma was separated. The plasma samples were immediately extracted.
  • the plasma samples 0.100 mL were transferred to plastic tubes.
  • the samples were extracted with 0.400 mL of 100 mM HCl in acetonitrile while being shaken vigorously for 30 seconds.
  • the samples were centrifuged at 10000 RPM for 5 minutes. The supernatant was separated.
  • the samples were frozen in dry ice and kept at ⁇ 80° C. until HPLC analysis. 20 microliter aliquots were injected into the HPLC for analysis.
  • Buffer B 90% acetonitrile 0.1% TFA
  • Control 2.5 mg/mL bendamustine hydrochloride, 4.25 mg/mL of mannitol in 0.9% NaCl; dose of 10 mg/kg
  • Inventive Composition 2.5 mg/mL bendamustine hydrochloride, 40% w/w sodium sulfobutyl ether ⁇ -cyclodextrin, 1% PI2080, 4.3 mg/g mannitol in water (prepared according to the procedure set forth in Example 9); dose of 10 mg/kg.
  • mice Female Sprague-Dawley rats (250-350 g). The animals were kept three per cage with an air filter cover under light (12 h light/dark cycle, light on at 06 h00) and controlled temperature 22° C.+/ ⁇ 1° C. All manipulations with the animals were performed under a sterilized laminar hood. The animals had ad libitum access to Purina mouse chow and water. The animals were fasted overnight and anesthetized, before dosing.
  • Inventive bendamustine composition and control were administered intravenously to rats in tail vein. Blood samples were collected after time intervals of 5, 15, 30, 45 min, 1, 1.5, 2 and 3 hrs post-injection. The rats were anesthetised by general inhalation of isoflurane. The blood samples were collected from the jugular vein with heparinized tube and kept on ice. The blood was immediately centrifuged, and plasma was separated. The plasma samples were immediately extracted.
  • the plasma samples 0.100 mL were transferred to plastic tubes.
  • the samples were extracted with 0.400 mL of 100 mM HCl in acetonitrile while being shaken vigorously for 30 seconds.
  • the samples were centrifuged at 10000 RPM for 5 minutes. The supernatant was separated.
  • the samples were frozen in dry ice and kept at ⁇ 80° C. until HPLC analysis. The aliquots of 20 microliters were injected into HPLC for analysis.
  • Buffer B 90% acetonitrile 0.1% TFA
  • Control 2.5 mg/mL bendamustine hydrochloride, 4.25 mg/mL of mannitol in 0.9% NaCl; dose of 10 mg/kg
  • Inventive Composition 2.5 mg/mL bendamustine hydrochloride, 40% w/w sodium sulfobutyl ether ⁇ -cyclodextrin, 3% protamine sulfate, 4.3 mg/g mannitol in water (produced according to the process described in Example 10); dose of 10 mg/kg.
  • mice Female Sprague-Dawley rats (250-350 g). The animals were kept three per cage with an air filter cover under light (12 h light/dark cycle, light on at 06 h00) and controlled temperature of 22° C.+/ ⁇ 1° C. All manipulations with the animals were performed under a sterilized laminar hood. The animals had ad libitum access to Purina mouse chow and water. The animals were fasted overnight and anesthetized, before dosing.
  • Bendamustine composition and control were administered intravenously to rats in tail vein. After time intervals 5, 15, 30, 45 min, 1, 1.5, 2 and 3 hrs post-injection, the blood samples were collected. The rats were anesthetized by general inhalation of isoflurane. The blood samples were collected from the jugular vein with heparinized tube and kept on ice. Blood was immediately centrifuged, and plasma was separated. The plasma samples were immediately extracted.
  • the plasma samples 0.100 mL were transferred to plastic tubes.
  • the samples were extracted with 0.400 mL of 100 mM HCl in acetonitrile while being shaken vigorously for 30 seconds.
  • the samples were centrifuged at 10000 RPM for 5 minutes. The supernatant was separated.
  • the samples were frozen in dry ice and kept at ⁇ 80° C. until HPLC analysis. 20 microliter aliquots were injected into HPLC for analysis.
  • Buffer B 90% acetonitrile 0.1% TFA
  • bendamustine hydrochloride 6 mg was dissolved in 1 mL of 30% w/w solution of sodium sulfobutyl ether ⁇ -cyclodextrin. The solution was preincubated at 10° C. for 15 minutes on ultrasonic bath; and then mixed with 1 mL of 0.1% solution of Luviquat FC370.
  • Luviquat FC370 (Polyquaternium-16) is a copolymer of vinylpyrrolidone and quaternized vinylimidazole (CAS No. 95144-24-4 (BASF). The sample was incubated on ultrasonic bath for 30 minutes at 10° C.
  • Luviquat HOLD Polyquaternium-466 is 1H-imidazolium, 1-ethenyl-3-methyl-methyl sulphate polymer with 1-ethenylhexahydro-2Hazepin-2-one and 1-ethenyl-2-pyrrolidinone, CAS No. 174761-16-1, (BASF). The sample was incubated in an ultrasonic bath for 30 minutes at 10° C.
  • bendamustine hydrochloride 6 mg were dissolved in 1 mL of 30% w/w solution of sodium sulfobutyl ether ⁇ -cyclodextrin. The solution was preincubated at 10° C. for 15 minutes in an ultrasonic bath. After that the solution was mixed with 1 mL of 0.1% solution of quaternized poly(vinylpyrrolidone-co-2-dimethylaminoethyl methacrylate). The sample was incubated in an ultrasonic bath for 30 minutes at 10° C.
  • bendamustine hydrochloride 6 mg were dissolved in 1 mL of 30% w/w solution of sodium sulfobutyl ether ⁇ -cyclodextrin. The solution was preincubated at 10° C. for 15 minutes in an ultrasonic bath. After that the solution was mixed with 1 mL of 0.1% solution of quaternized poly(vinylpyrrolidone-co-2-dimethylaminoethyl methacrylate). The sample was incubated in an ultrasonic bath for 30 minutes at 10° C.
  • bendamustine hydrochloride 6 mg were dissolved in 1 mL of a 30% w/w solution of sodium sulfobutyl ether ⁇ -cyclodextrin. The solution was preincubated at 10° C. for 15 minutes in an ultrasonic bath. After that the solution was mixed with 1 mL of a 0.05% solution of quaternized poly(bis(2-chloroethyl)ether-alt-1,3-bis[3-dimethylamino)propyl]-urea. The sample was incubated in an ultrasonic bath for 30 minutes at 10° C.
  • LMWP Low Molecular Weight Protamine
  • thermolysin solution was added to the protamine sulfate solution, followed by 70 microliters of 1 M aqueous calcium chloride. The mixture was incubated for 30 minutes at room temperature. 0.7 mL 0.7 M EDTA solution was added to the mixture. The mixture was lyophilized.
  • the dry material was redissolved in 0.2% aqueous acetic acid, 100 mg per 1 mL and filtered through 0.22 micrometer filter. 5 mL of the solution was injected into RP-HPLC column Vaydac 218TPI52050, 5 ⁇ 25 cm. The sample was eluted with gradient ethanol in water comprising 0.2% acetic acid. The fraction containing the product was collected and lyophilized.
  • Example 20 The composition of Example 20 was lyophilised. The product was amorphous white solid, soluble in water. The product before use was reconstituted with 1.536 mL of water.
  • H460, RPMI8226, and MDA-MB-231 cells were maintained in appropriate medium, containing 10% foetal bovine serum (FBS) and antibiotics.
  • FBS foetal bovine serum
  • SBECD sodium sulfobutyl ether ⁇ -cyclodextrin
  • LMWP low molecular weight protamine
  • IC50 values were estimated for bendamustine, bendamustine formulated in SBECD, and bendamustine formulated in SBECD/LMWP.
  • Table 4 shows the increase in BM potency produced by formulation of the drug in SBECD or SBECD/LMWP.
  • ratios of BM IC50 to IC50 of BM in SBECD or SBECD/LMWP formulation were calculated. For each cell line, these ratios represent averages for 3-12 independent experiments.
  • SBECD formulation increased potency of BM, decreasing its IC50. Addition of LMWP to SBECD formulation further substantially decreased BM IC50.
  • MDA-MB-231 cells effects of both formulations were not significantly different. For these three cell lines, average decrease in IC50 of BM was 1.5- and 2.2-fold for SBECD and SBECD/LMWP, respectively.
  • BM and SBECD/LMWP formulation (40 mg/ml BM in 20% SBECD, 1% LMWP) were incubated in DMEM medium containing 10% FBS for 0, 1, or 4 h and then were added in varying concentrations to RPMI8226 cells.
  • concentrations of SBECD and LMWP were kept constant in culture medium at 0.1 and 0.05%, respectively. Cells were then grown for 72 h. The drug cytotoxicity was evaluated using WST-1 procedure. The results are presented in Tables 5 and 6 below.
  • IC50 of bendamustine and BM/SBECD/LMWP formulation pre- incubated in cell culture medium for 0, 1, or 4 h, in RPMI8226 cells.
  • Time of pre- IC50 of bendamustine, uM incubation, h BM BM/SBECD/LMWP 0 62 32 1 106 38 4 390 53 IC50, TGI, and LC50 parameters were calculated for each time of pre-incubation.
  • IC50 - concentration of a drug that causes 50% growth inhibition of cells TGI - concentration of a drug that causes total growth inhibition of cells
  • LC50 - concentration of a drug that causes 50% death of cells The results show that the composition of BM, SBECD and LMWP retains potency longer than BM alone.
  • RPMI8226, H69, MDA-MB-231, and H460 cells were maintained in appropriate medium, containing 10% FBS and antibiotics.
  • bendamustine, and bendamustine formulated in SBECD/LMWP 40 mg/ml BM in 20% SBECD, 1% LMWP were added in different concentrations to cell cultures and cells were grown for three days.
  • the drug cytotoxicity was evaluated using WST-1 procedure. The results are presented in the Table 8 below.
  • compositions of this invention possess enhanced cytotoxicity.
  • compositions were prepared for testing:
  • Control 5 mg/mL bendamustine hydrochloride, 10.2 mg/mL of mannitol in 0.9% NaCl; dose of 10 mg/kg
  • bendamustine hydrochloride 20% w/w sodium sulfobutyl ether ⁇ -cyclodextrin, 1% LMWP, 10.2 mg/g mannitol in water; dose of 10 mg/kg.
  • mice Female Sprague-Dawley rats (250-350 g). The animals were kept three per cage with an air filter cover under light (12 h light/dark cycle, light on at 06 h00) and controlled temperature 22° C.+/ ⁇ 1° C. All manipulations with the animals were performed under a sterilized laminar hood. The animals had ad libitum access to Purina mouse chow and water. The animals were fasted overnight and anesthetized, before dosing.
  • the bendamustine compositions and control were administered intravenously to rats via a tail vein.
  • Blood samples were collected 5, 15, 30, 45 min, 1, 1.5, 2, 3 and 4 hrs post-injection.
  • the rats were anesthetized by general inhalation of isoflurane.
  • the blood samples were collected from the jugular vein with a heparinized tube and kept on ice. The sample was immediately centrifuged, and the plasma separated. The plasma samples were immediately extracted.
  • the plasma samples 0.100 mL were transferred to plastic tubes.
  • the samples were extracted with 0.400 mL of 100 mM HCl in acetonitrile while being shaken vigorously for 30 seconds.
  • the samples were centrifuged at 10000 RPM for 5 minutes. The supernatant was separated.
  • the samples were frozen in dry ice and kept at ⁇ 80° C. until HPLC analysis. The aliquots of 20 microliters were injected into HPLC for analysis.
  • Buffer B 90% acetonitrile 0.1% TFA
  • mice Female Charles Rivers C57B1/6 mice, aged 5 to 6 weeks, were purchased from Charles River Canada Inc. The animals were kept 5 per cage with an air filter cover under light (12 light/dark cycle, light on at 6H00) and temperature (22° ⁇ 1° C.)-controlled environment. All manipulations of animals were performed under a sterilized laminar hood. The animals had ad libitum access to Purina mouse chow (Pro Lab PMH 4018, Trademark of Agway, Syracuse, N.Y.) and water. These animal studies were conducted according to the “Guidelines for Care and Use of Experimental Animals”.
  • Lewis Lung carcinoma 3LL cells were cultured in the appropriated culture medium. The cells were harvested in their logarithmic growth phase for the preparation of tumor implantation.
  • Lewis Lung carcinoma 3LL cells (2.0 to 5.0 ⁇ 105 cells in 200 ul PBS) were implanted intravenously by tail vein to establish experimental lung metastasis tumor models.
  • the treatments were performed on day after tumor implantation.
  • the animals were dosed with the following dosing solutions.
  • compositions are Compositions:
  • BM non-formulated bendamustine
  • Metastasis formation was evaluated by counting the numbers of metastasis spots on the lung surface. Routine metastasis examination were done for all organs at the end of the study.
  • results show statistically significant improvement of efficacy of the composition comprising SBECD and LMWP vs. non-formulated drug.
  • balb/c mice aged 5 to 6 weeks were purchased from Charles River Canada Inc.
  • the animals were kept 5 per cage with an air filter cover under light (12 light/dark cycle, light on at 6H00) and temperature (22° C. ⁇ 1° C.)-controlled environment. All manipulations of animals were performed under a sterilized laminar hood. The animals had ad libitum access to Purina mouse chow (Pro Lab PMH 4018, Trademark of Agway, Syracuse, N.Y.) and water. These animal studies were conducted according to the “Guidelines for Care and Use of Experimental Animals”.
  • Human breast cancer cells MDA-MB 231 were cultured in the appropriated culture medium. The cells were harvested in their logarithmic growth phase for the preparation of tumor implantation.
  • Human tumor or myeloma cells (2.5 to 5.0 ⁇ 10 6 cells) were implanted subcutaneously in 0.200 mL of medium containing 30% Matrigel on the two flanks of balb/c nu/nu mice through a 1 to 2 cm long 20-gauge needle.
  • compositions are Compositions:
  • Subcutaneous solid tumor measurements were performed on the day of first injection and at 3- to 4-day intervals thereafter.
  • the two largest perpendicular diameters of each tumor were measured with calipers and tumor sizes were estimated using the formula:
  • TV L ⁇ W/2 where TV: tumor volume; L: length; W: width.
  • compositions are Compositions:
  • the treatment was performed on days 1, 2, 9, and 10.
  • Table 14 shows the effect of BM and its compositions on the growth of tumors.
  • compositions are Compositions:
  • the treatment was performed on days 1, 2, 9, and 10.
  • SBECD phosphate buffer
  • compositions were prepared and tested:
  • Composition 30-1 0.6 mg/mL BM in 4% SBECD prepared by dissolving BM in SBECD/PB
  • Composition 30-2 0.6 mg/mL BM in 4% SBECD and 0.2% LMWP, prepared by dissolving BM in SBECD/PB, and adding LMWP
  • Composition 30-3 0.6 mg/mL BM in 4% SBECD and 1% LMWP, prepared by dissolving BM in SBECD/PB, and adding LMWP
  • Composition 30-4 0.6 mg/mL BM in 4% SBECD and 0.2% LMWP, prepared by dissolving LMWP in SBECD/PB, and adding BM
  • Composition 30-5 0.6 mg/mL BM in 4% SBECD and 0.2% LMWP, prepared by dissolving LMWP in SBECD/PB, and adding BM.
  • compositions were incubated at 25° C., and were periodically analyzed by HPLC as follows. 10 ⁇ L samples were separated on HPLC using Waters SymmetryShield RP-18 3.5 ⁇ m column (4.6 ⁇ 50 mm) at the flow of 1.5 mL/min of acetonitrile-water gradient containing 0.1% TFA. Peak detection was performed by means of UV absorption detection at 260 nm. The area of the peak of bendamustine was used to evaluate the rate of drug decomposition in the first order kinetics model. The results expressed as decomposition half times (T1/2) are presented in Table 17 below.
  • composition T1 ⁇ 2 Control: 0.6 mg/mL BM 44 min
  • Composition 30-1 4% SBECD, 0.6 mg/mL BM 642 min
  • Composition 30-2 4% SBECD, 0.6 mg/mL BM, 0.2% LMWP 707 min
  • Composition 30-3 4% SBECD, 0.6 mg/mL BM, 1% LMWP 789 min
  • Composition 30-4 4% SBECD, 0.2% LMWP, 0.6 mg/mL BM 673 min
  • Composition 30-5 4% SBECD, 1% LMWP, 0.6 mg/mL BM 729 min
  • Heparinized human plasma was spiked, 20 ⁇ L into 780 ⁇ L of plasma, with the following bendamustine (BM) compositions:
  • Composition 31-A 0.6 mg/mL BM in 4% SBECD, prepared by dissolving BM in 4% (w/w) solution of SBECD in water
  • Composition 31-B 0.6 mg/mL BM in 8% SBECD, prepared by dissolving BM in 8% (w/w) solution of SBECD in water
  • Composition 31-C 0.6 mg/mL BM in 20% SBECD, prepared by dissolving BM in 20% (w/w) solution of SBECD in water
  • Composition 31-D 0.6 mg/mL BM in 40% SBECD, prepared by dissolving BM in 40% (w/w) solution of SBECD in water
  • Composition 31-1 0.6 mg/mL BM in 4% SBECD and 3% PI2080, prepared by dissolving BM in 4% (w/w) solution of SBECD in water, and adding PI2080
  • Composition 31-2 0.6 mg/mL BM in 8% SBECD and 3% PI2080, prepared by dissolving BM in 8% (w/w) solution of SBECD in water, and adding PI2080
  • Composition 31-3 0.6 mg/mL BM in 20% SBECD and 3% PI2080, prepared by dissolving BM in 20% (w/w) solution of SBECD in water, and adding PI2080
  • Composition 31-4 0.6 mg/mL BM in 40% SBECD and 3% PI2080, prepared by dissolving BM in 40% (w/w) solution of SBECD in water, and adding PI2080
  • the concentration of bendamustine in plasma after spiking was initially 0.015 mg/mL.
  • the spiked plasma samples were incubated at 37° C.
  • a sample of 50 ⁇ L was periodically withdrawn from spiked plasma, and transferred into 200 ⁇ L of 100 mM HCl solution in acetonitrile, mixed and centrifuged.
  • 50 ⁇ L of the supernatant was diluted 20 times with 95% acetonitrile, then 20 ⁇ L of diluted samples were separated on Waters SymmetryShield RP18 3.5 ⁇ m column (4.6 ⁇ 50 mm) using gradient of acetonitrile (0.1% TFA) in water (0.1% TFA), flow 1.5 mL/min.
  • Peak detection was performed by means of fluorescence detection with extinction at 327 nm and emission at 420 nm.
  • the area of the peak of Bendamustine was used to evaluate the rate of drug decomposition in the first order kinetics model.
  • the results expressed as decomposition half times (T1/2) are presented in Table 18 below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US12/711,979 2009-02-25 2010-02-24 Bendamustine cyclopolysaccharide compositions Active 2030-10-29 US8436032B2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
KR1020117022330A KR101798951B1 (ko) 2009-02-25 2010-02-24 벤다무스틴 환형다당류 조성물
CN2010800183017A CN102421451B (zh) 2009-02-25 2010-02-24 苯达莫司汀环多糖组合物
RU2011138844/15A RU2591804C2 (ru) 2009-02-25 2010-02-24 Композиции бендамустина и циклополисахарида
AU2010217297A AU2010217297A1 (en) 2009-02-25 2010-02-24 Bendamustine cyclopolysaccharide compositions
CN2012104076231A CN102935080A (zh) 2009-02-25 2010-02-24 苯达莫司汀环多糖组合物
CA2753641A CA2753641C (en) 2009-02-25 2010-02-24 Bendamustine cyclopolysaccharide compositions
US12/711,979 US8436032B2 (en) 2009-02-25 2010-02-24 Bendamustine cyclopolysaccharide compositions
PCT/IB2010/000502 WO2010097700A1 (en) 2009-02-25 2010-02-24 Bendamustine cyclopolysaccharide compositions
RU2016124871A RU2734236C2 (ru) 2009-02-25 2010-02-24 Композиции бендамустина и циклополисахарида
ES10745872.1T ES2525257T3 (es) 2009-02-25 2010-02-24 Composiciones de ciclopolisacárido y de bendamustina
JP2011550669A JP5654498B2 (ja) 2009-02-25 2010-02-24 ベンダムスチン環状多糖組成物
EP10745872.1A EP2400987B1 (de) 2009-02-25 2010-02-24 Bendamustin-cyclopolysaccharidzusammensetzungen
US13/793,442 US8703964B2 (en) 2009-02-25 2013-03-11 Bendamustine cyclopolysaccharide compositions

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20854109P 2009-02-25 2009-02-25
US26994409P 2009-07-01 2009-07-01
US27136409P 2009-07-20 2009-07-20
US27929309P 2009-10-19 2009-10-19
US12/711,979 US8436032B2 (en) 2009-02-25 2010-02-24 Bendamustine cyclopolysaccharide compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/793,442 Continuation US8703964B2 (en) 2009-02-25 2013-03-11 Bendamustine cyclopolysaccharide compositions

Publications (2)

Publication Number Publication Date
US20100216858A1 US20100216858A1 (en) 2010-08-26
US8436032B2 true US8436032B2 (en) 2013-05-07

Family

ID=42631521

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/711,979 Active 2030-10-29 US8436032B2 (en) 2009-02-25 2010-02-24 Bendamustine cyclopolysaccharide compositions
US13/793,442 Active US8703964B2 (en) 2009-02-25 2013-03-11 Bendamustine cyclopolysaccharide compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/793,442 Active US8703964B2 (en) 2009-02-25 2013-03-11 Bendamustine cyclopolysaccharide compositions

Country Status (12)

Country Link
US (2) US8436032B2 (de)
EP (2) EP2400987B1 (de)
JP (1) JP5654498B2 (de)
KR (1) KR101798951B1 (de)
CN (2) CN102935080A (de)
AU (1) AU2010217297A1 (de)
CA (1) CA2753641C (de)
ES (2) ES2525257T3 (de)
HU (1) HUE038234T2 (de)
NO (1) NO2792369T3 (de)
RU (2) RU2734236C2 (de)
WO (1) WO2010097700A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220265829A1 (en) * 2012-03-20 2022-08-25 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2024091826A1 (en) 2022-10-25 2024-05-02 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525257T3 (es) 2009-02-25 2014-12-19 Supratek Pharma, Inc. Composiciones de ciclopolisacárido y de bendamustina
RS55491B2 (sr) 2010-01-28 2020-11-30 Eagle Pharmaceuticals Inc Formulacije bendamustina
WO2011103150A2 (en) * 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US8383663B2 (en) * 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
US9376395B2 (en) * 2011-09-18 2016-06-28 Purdue Pharmaceuticals Products L.P. Pharmaceutical compositions
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
EP2827863B1 (de) 2012-03-20 2019-01-16 Eagle Pharmaceuticals, Inc. Flüssige zusammensetzung zur verwendung bei einem verfahren zur behandlung bendamustin-reaktiver zustände bei patienten mit reduziertem volumen zur verabreichung
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
EP2925327B1 (de) * 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolon zur behandlung, verminderung oder milderung von symptomen der wochenbettdepression
CN109953954A (zh) * 2013-08-27 2019-07-02 V·沃道里斯 苯达莫司汀医药组合物
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
CA3040155C (en) 2016-10-11 2024-01-16 Euro-Celtique S.A. Compound for use in the treatment of hodgkin lymphoma
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
MX2020003511A (es) 2017-10-05 2020-07-22 Tube Pharmaceuticals Gmbh Formulaciones orales de bendamustina.
US11730815B2 (en) * 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
EP4134068A4 (de) * 2020-04-09 2024-02-07 Bika Biotechnology (Guangzhou) Co., Ltd. Bendamustinzusammensetzung und verwendung davon
CN111557904A (zh) * 2020-04-09 2020-08-21 比卡生物科技（广州）有限公司 苯达莫司汀组合物及其用途

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068226A (en) * 1987-12-07 1991-11-26 Cyclex, Inc. Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US6583125B2 (en) 1992-06-19 2003-06-24 Supergen, Inc. Formulation of nitrogen mustard
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US20050222163A1 (en) * 2004-03-30 2005-10-06 Pfizer Inc Combinations of signal transduction inhibitors
US20050220758A1 (en) * 2002-02-06 2005-10-06 Hans-Peter Zobel Lyophilised preparation comprising immunocytokines
US20060159713A1 (en) 2005-01-14 2006-07-20 Cephalon, Inc. Bendamustine pharmaceutical compositions
CA2593715A1 (en) 2005-01-28 2006-08-10 Brigham Young University Bacterial glycolipid activation of cd1d-restricted nkt cells
CN1846685A (zh) 2006-01-25 2006-10-18 济南帅华医药科技有限公司 含苯达莫司汀和其增效剂的缓释注射剂
CN101219113A (zh) 2008-01-28 2008-07-16 济南帅华医药科技有限公司 含苯达莫司汀的复方抗癌缓释注射剂
CA2679919A1 (en) 2007-03-02 2008-09-12 University Of Wollongong Compositions and methods for delivery of anti-cancer agents
US20080255510A1 (en) * 2006-11-20 2008-10-16 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080299166A1 (en) 2002-04-19 2008-12-04 Lajos Szente Novel biomaterials, their preparation and use
CN101606934A (zh) 2009-07-27 2009-12-23 江苏奥赛康药业有限公司 盐酸苯达莫司汀组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE59607089D1 (de) * 1995-03-10 2001-07-19 Roche Diagnostics Gmbh Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
CA2214889C (en) * 1995-03-10 2005-05-24 Hans Koll Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and a process for the production thereof
KR20050090430A (ko) * 2002-12-31 2005-09-13 알투스 파마슈티컬스 인코포레이티드 인간 성장 호르몬 결정 및 이것의 제조 방법
KR20070007075A (ko) * 2003-12-31 2007-01-12 사이덱스 인크 술포알킬 에테르 시클로덱스트린 및 코르티코스테로이드를함유한 흡입용 제형
US20070212306A1 (en) * 2004-06-07 2007-09-13 Quay Steven C Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides
WO2006013084A1 (en) * 2004-08-03 2006-02-09 Royal College Of Surgeons In Ireland Phenytoin formulations, and uses thereof in wound healing
JP2008519032A (ja) * 2004-11-03 2008-06-05 キュラジェン コーポレイション Ｆｇｆ−２０の調合物、生成方法および使用
TW200621240A (en) * 2004-11-05 2006-07-01 Salmedix Inc Cancer treatments
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
UA94036C2 (ru) * 2005-01-14 2011-04-11 Сефалон, Инк. Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
JP2010509363A (ja) 2006-11-08 2010-03-25 ノババックス，インコーポレイテッド 固体剤形の多相医薬組成物の製造方法
ES2525257T3 (es) 2009-02-25 2014-12-19 Supratek Pharma, Inc. Composiciones de ciclopolisacárido y de bendamustina

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5068226A (en) * 1987-12-07 1991-11-26 Cyclex, Inc. Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies
US6583125B2 (en) 1992-06-19 2003-06-24 Supergen, Inc. Formulation of nitrogen mustard
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US20050220758A1 (en) * 2002-02-06 2005-10-06 Hans-Peter Zobel Lyophilised preparation comprising immunocytokines
US20080299166A1 (en) 2002-04-19 2008-12-04 Lajos Szente Novel biomaterials, their preparation and use
US20050222163A1 (en) * 2004-03-30 2005-10-06 Pfizer Inc Combinations of signal transduction inhibitors
US20060159713A1 (en) 2005-01-14 2006-07-20 Cephalon, Inc. Bendamustine pharmaceutical compositions
CA2593582A1 (en) 2005-01-14 2006-07-20 Cephalon, Inc. Bendamustine pharmaceutical compositions
CA2593715A1 (en) 2005-01-28 2006-08-10 Brigham Young University Bacterial glycolipid activation of cd1d-restricted nkt cells
CN1846685A (zh) 2006-01-25 2006-10-18 济南帅华医药科技有限公司 含苯达莫司汀和其增效剂的缓释注射剂
US20080255510A1 (en) * 2006-11-20 2008-10-16 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
CA2679919A1 (en) 2007-03-02 2008-09-12 University Of Wollongong Compositions and methods for delivery of anti-cancer agents
CN101219113A (zh) 2008-01-28 2008-07-16 济南帅华医药科技有限公司 含苯达莫司汀的复方抗癌缓释注射剂
CN101606934A (zh) 2009-07-27 2009-12-23 江苏奥赛康药业有限公司 盐酸苯达莫司汀组合物

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Chatterji et al., "Kinetick of Chlorambucil Hydrolysis Using High-Pressure Liquid Chromatography", J Pharm Sci 71 (1):50-54 (1982).
Davis et al. Nature Reviews (2004); 3; 1023-1035. *
Evjen, T.J., "Developments of Improved Bendamustin-Liposomes", Thesis for the degree of Master of Pharmacy, Department of Pharmaeutics and Biopharmaceutics, Institute of Pharmacy, Faculty of Medicine, University of Tormso (2007).
Haase et al., "Untersuchungen zur Plasmaeiweibetabindung von Bendamustin (Cytostasan(R)) und Ambazon", Z. Klin. Med. 45(14):1267-1271 (1990).
Haase et al., "Untersuchungen zur Plasmaeiweiβbindung von Bendamustin (Cytostasan(R)) und Ambazon", Z. Klin. Med. 45(14):1267-1271 (1990).
International Search Report and Written Opinion from corresponding PCT/IB2010/000502.
Loftsson et al. (J. Pharmaceutical Science (1996) 85(10); 1017-1025). *
Maas et al., "Stabilitat von Bendamustinhydrochlorid in Infusionsloungen", Die Pharmazie 49:775-777 (1994 ).
Meyer-Losic et al., "DTS-108, A Novel Peptidic Prodrug fo SN38; In vivo Efficacy and Toxicokinetic Studies", Clin Cancer Res 14(7):2145-2153 (2008).
Pencheva et al., HPLC Study on the stability of bendamustine hydrochloride immobilized onto polyphosphoesters, J Pharm Biomed Anal (2008) doi:10.1016/j.pba.2008.09.001.
Preiss et al., "Untersuchungen zur Pharmakokinetik von Bendamustin (Cytostasan(R)) am Menschem", Pharmazie 40:782-784 (1985).
Teichert et al., "Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride", Cancer Chemother Pharmacol 59:759-770 (2007).

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220265829A1 (en) * 2012-03-20 2022-08-25 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2024091826A1 (en) 2022-10-25 2024-05-02 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Also Published As

Publication number Publication date
RU2016124871A (ru) 2018-12-04
US8703964B2 (en) 2014-04-22
CN102421451A (zh) 2012-04-18
EP2792369B1 (de) 2018-04-18
NO2792369T3 (de) 2018-09-15
ES2525257T3 (es) 2014-12-19
EP2792369A1 (de) 2014-10-22
AU2010217297A1 (en) 2011-10-20
US20100216858A1 (en) 2010-08-26
US20130190372A1 (en) 2013-07-25
CN102421451B (zh) 2013-11-06
CA2753641A1 (en) 2010-09-02
JP5654498B2 (ja) 2015-01-14
KR20120015294A (ko) 2012-02-21
JP2012519657A (ja) 2012-08-30
EP2400987B1 (de) 2014-09-03
RU2011138844A (ru) 2013-04-10
CA2753641C (en) 2014-09-16
ES2675620T3 (es) 2018-07-11
RU2591804C2 (ru) 2016-07-20
WO2010097700A1 (en) 2010-09-02
EP2400987A1 (de) 2012-01-04
EP2400987A4 (de) 2012-08-22
HUE038234T2 (hu) 2018-10-29
KR101798951B1 (ko) 2017-11-20
RU2734236C2 (ru) 2020-10-13
CN102935080A (zh) 2013-02-20
RU2016124871A3 (de) 2019-11-11

Similar Documents

Publication Publication Date Title
US8703964B2 (en) Bendamustine cyclopolysaccharide compositions
US20220265829A1 (en) Formulations of bendamustine
AU2019219792B2 (en) Bendamustine anionic-cationic cyclopolysaccharide compositions
JP5380549B2 (ja) ボリコナゾール含有の薬物製剤及びその調製方法
KR20090084925A (ko) 피모벤단과 사이클로덱스트린의 복합물을 포함하는 액상 제제
US20110207764A1 (en) Cyclopolysaccharide compositions
US20200297849A1 (en) Stable liquid pharmaceutical compositions comprising bendamustine
US20240148696A1 (en) Lyophilized bendamustine-cyclodextrin composition

Legal Events

Date Code Title Description
AS Assignment

Owner name: SUPRATEK PHARMA INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:POPEK, THOMASZ;PATEL, KISHORE;ALAKHOV, VALERY;AND OTHERS;REEL/FRAME:024984/0543

Effective date: 20100914

STCF Information on status: patent grant

Free format text: PATENTED CASE

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 4

SULP Surcharge for late payment
AS Assignment

Owner name: SOFTKEMO PHARMA CORP., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SUPRATEK PHARMA INC.;REEL/FRAME:045181/0467

Effective date: 20180122

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 12